Loading...
•
Dec 31, 2022
Nuvation Bio Q4 2022 Earnings Report
Reported financial results for Q4 and full year 2022 and provided a business update.
Key Takeaways
Nuvation Bio reported its Q4 and full year 2022 financial results, highlighting the initiation of dosing in the Phase 1b study of NUV-868 and a strong cash position of $661.0 million.
Dosed first patient in both regimens of Phase 1b study of NUV-868 with olaparib or enzalutamide.
Dosing is ongoing in the Phase 1 monotherapy study of NUV-868.
Nominated an undisclosed Drug-Drug Conjugate (DDC) as the first clinical candidate.
Cash, cash equivalents, and marketable securities totaled $661.0 million as of December 31, 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...